This report was our free report of the day on a previous date — it has since expired.
Today's free report is available: FNGR 10-Q — Revenue collapses 92% to $650K on working-capital constraints; $4.3M convertible raised
Get notified when ATYR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Securities Litigation (new) — Two class action lawsuits filed alleging false statements about efzofitimod, with amended complaint adding CFO as defendant in May 2026.
aTyr faces securities litigation, Phase 3 trial failure, and Japan partnership loss
Filed May 15, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 7, 2025 · ~2 min read
Key Changes
-
high
EFZO-FIT Phase 3 trial missed primary endpoint of steroid reduction; FDA requires new Phase 3 with different design, higher dose, and FVC as primary endpoint instead of steroid reduction.
MD&A: Clinical Development verify on EDGAR → -
high
Kyorin terminated Japan partnership without cause, eliminating $155 million in potential milestone payments and all future royalties on Japan sales.
MD&A: Partnerships verify on EDGAR → -
high
Two securities class action lawsuits filed October 2025 allege false statements about efzofitimod; amended complaint in May 2026 adds CFO as defendant, with motion to dismiss deadline July 17, 2026.
Legal Proceedings verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Partner
Trade ATYR commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify